• Corpus ID: 198111007

American Socie ty of Cl in ica l Oncology 2003 Update on the Role of Bisphosphonates and Bone Heal th Issues in Women With Breast Cancer

@inproceedings{Hillner2003AmericanST,
  title={American Socie ty of Cl in ica l Oncology 2003 Update on the Role of Bisphosphonates and Bone Heal th Issues in Women With Breast Cancer},
  author={Bruce E. Hillner and James N. Ingle and Rowan T. Chlebowski and Julie R. Gralow and Gary C. Yee and Nora Anita Janjan and Jane A. Cauley and Brent A. Blumenstein and Kathy S. Albain and Allan Lipton and Susan Brown},
  year={2003}
}
Purpose: To update the 2000 ASCO guidelines on the role of bisphosphonates in women with breast cancer and address the subject of bone health in these women. Results: For patients with plain radiographic evidence of bone destruction, intravenous pamidronate 90 mg delivered over 2 hours or zoledronic acid 4 mg over 15 minutes every 3 to 4 weeks is recommended. There is insufficient evidence supporting the efficacy of one bisphosphonate over the other. Starting bisphosphonates in women who… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 61 REFERENCES

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.

BACKGROUND Bisphosphonates such as pamidronate disodium inhibit osteoclast-induced bone resorption associated with cancer that has metastasized to bone. METHODS Women with stage IV breast cancer

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.

  • S. AliF. Esteva A. Lipton
  • Medicine, Chemistry
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2001
Prolonged treatment with the potent bisphosphonates pamidronate and zoledronic acid seems to be well tolerated and should be studied in prospective, randomized studies to document prolonged skeletal efficacy.

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.

Chemotherapy-induced ovarian failure causes rapid bone loss in premenopausal breast cancer patients, which is significantly reduced by clodronate, and women older than 40 years are at particularly high risk.

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

PURPOSE To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective role

The role of disodium pamidronate in the management of bone pain due to malignancy

Pamidronate represents a further valid therapy to add to an already consolidated list of therapies such as radiotherapy, chemotherapy, hormone therapy and orthopaedic intervention in the pain management of patients with bone metastases.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

The risk for osteolytic bone lesion complications in metastatic breast cancer was significantly decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least 2 years.

Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Pamidronate is the drug of choice for first-line use in the management of patients with tumour-induced hypercalcaemia and Paget's disease of bone and is the treatment of choice where oral bisphosphonates are not an option.

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.

Bisphosphonates for cancer patients: why, how, and when?

Because BPs are providing supportive care, reducing the rate of skeletal morbidity but evidently not abolishing it, the criteria for stopping their administration have to be different from those used for classic antineoplastic drugs, and they should be stopped when metastatic bone disease is progressing.

Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases.
...